Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.See eligibility criteria
- Pre-identified dyslipidemic patients selected to receive PCSK9 inhibitor treatment at Mayo Clinic. The drug will be prescribed by a cardiologist as part of the patient’s routine care.
- Pediatric patients younger than 18 years of age.
- Pregnant women of any age.
- Subjects who have not provided MN research authorization.